Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 4,238 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dry Eye Disease Study With Brimonidine

NCT03418727
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

NCT06280391
View directory record Official record
Conditions
Bronchiectasis
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Westminster, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 8:40 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

NCT03196076
View directory record Official record
Conditions
Chronic Kidney Diseases, Cystic Kidney Disease
Interventions
Perflutren Lipid microsphere
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Study Buddy (an ECA Oncology Trial Advisor) for Cancer Trials

NCT02742740
View directory record Official record
Conditions
Patient Satisfaction, Patient Compliance, Guideline Adherence
Interventions
Chemo Buddy
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 28, 2026, 8:40 AM EDT
Not yet recruiting Not applicable Interventional

AI-CONECT: A Conversational AI for Early Dementia Prevention in Socially-Isolated Older Adults

NCT07701668
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Social Isolation
Interventions
AI-based conversational intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
75 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

Effect of Leflunomide on T Cell Proliferation in HIV-Infected Patients

NCT00101374
View directory record Official record
Conditions
HIV Infections
Interventions
Leflunomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Test a New Drug to Treat Major Depression

NCT00976560
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
GW856553, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Hoffman Estates, Illinois • Park Ridge, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Duration of Effect of Acidform Gel on Vaginal pH

NCT02693418
View directory record Official record
Conditions
Healthy
Interventions
Acidform 5 g, Placebo 4 g, Acidform 4 g, Acidform 3 g
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae

NCT02440022
View directory record Official record
Conditions
Arteriovenous Fistula
Interventions
Lutonix DCB, Standard Balloon Angioplasty Catheter, Percutaneous Transluminal Angiography
Combination Product · Device · Procedure
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 28, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 4 Interventional

Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.

NCT00414102
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 28, 2026, 8:40 AM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis

NCT01112722
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Apitox, purified honeybee toxin, lyophilized in saline, histamine
Biological
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
15
States / cities
Gulf Shores, Alabama • Tucson, Arizona • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis

NCT01154153
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and/or Seasonal
Interventions
Placebo nasal spray, Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 12 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Cypress, California • Stockbridge, Georgia • North Dartmouth, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

NCT00966277
View directory record Official record
Conditions
Pancreatic Cancer, Venous Thromboembolism
Interventions
Dalteparin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 28, 2026, 8:40 AM EDT
Recruiting Phase 2 Interventional

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

NCT07601074
View directory record Official record
Conditions
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions
Lopinavir / ritonavir
Drug
Lead sponsor
Daré Bioscience, Inc.
Industry
Eligibility
22 Years to 50 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 28, 2026, 8:40 AM EDT